Key result
Multidisciplinary polypharmacy management linked to ~15% lower 90-day readmission risk vs historical controls in older adults.
Why the study?
Polypharmacy is associated with adverse outcomes in older adults, prompting Korea's National Health Insurance Service to implement a hospital-based pilot polypharmacy management program whose clinical and economic effectiveness required evaluation.
Does a hospital-based polypharmacy management program reduce 90-day readmission and healthcare costs in hospitalized older adults with polypharmacy?
Cohort (n=2,260)
Yes
Does a hospital-based polypharmacy management program reduce 90-day readmission and healthcare costs in hospitalized older adults with polypharmacy?
Hazard Ratio: 0.85 (95% CI 0.75–0.96)
Absolute Event Rate: 42.9% vs 47.5%
p-value: p=0.029
A multidisciplinary polypharmacy management program for hospitalized older adults significantly reduced 90-day readmissions and generated substantial cost savings.
May support lower readmission risk with structured polypharmacy programs in older adults; leaves open confirmation in randomized trials before practice change.
Polypharmacy is a significant health concern associated with adverse outcomes in older adults. To mitigate these risks, Korea’s National Health Insurance Service implemented a hospital-based, pilot polypharmacy management program. We aimed to evaluate the clinical and economic effectiveness of the polypharmacy management program in beneficiaries aged ≥ 65 years. This retrospective cohort study evaluated the polypharmacy management program implemented across 34 hospitals (2020–21). The program targeted hospitalized patients with at least one chronic condition receiving either ten or more medications or five or more medications plus an additional high-risk factor. To address the lack of randomization, an external historical control group was established by linking pilot data with the nationwide National Health Insurance Service claims database. Propensity score matching was performed on the entire cohort with subsequent analyses restricted to those aged ≥ 65 years. The primary outcome was 90-day readmission, analyzed using Cox proportional hazards regression. A cost–benefit analysis was performed from payer and societal perspectives. The final analysis included 1135 intervention and 1125 control patients. Polypharmacy management program participants showed a lower risk of readmission compared with controls (adjusted hazard ratio = 0.85; 95% confidence interval 0.75–0.96). While emergency department visits did not differ significantly, the intervention group incurred significantly lower hospitalization costs (USD$6400 vs USD$6740, P = 0.005). The program demonstrated economic viability, yielding a benefit-cost ratio of 3.8 from a payer perspective. The polypharmacy management program effectively reduced readmissions and generated substantial cost savings. These findings underscore the importance of integrating data-driven medication management into national healthcare strategies to improve patient safety and financial sustainability.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2026) conducted a cohort in Polypharmacy in hospitalized older adults (n=2,260). Polypharmacy management program (multidisciplinary medication review and reconciliation) vs. External historical control group (usual care) was evaluated on 90-day hospital readmission (HR 0.85, 95% CI 0.75-0.96, p=0.029). A multidisciplinary polypharmacy management program significantly reduced the risk of 90-day hospital readmission (adjusted HR 0.85) compared to historical controls in hospitalized older adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: